These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 37208427)
1. Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema. Hein M; Vukmirovic A; Constable IJ; Raja V; Athwal A; Freund KB; Balaratnasingam C Sci Rep; 2023 May; 13(1):8128. PubMed ID: 37208427 [TBL] [Abstract][Full Text] [Related]
2. Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study). Korobelnik JF; Gaucher D; Baillif S; Creuzot-Garcher C; Kodjikian L; Weber M Ophthalmologica; 2023; 246(2):71-80. PubMed ID: 36646050 [TBL] [Abstract][Full Text] [Related]
3. Optical coherence tomography classifications of diabetic macular edema and response to aflibercept: One-year follow-up outcomes in a Chinese population. Gu Z; Xi T; Zhang C; Yang G Medicine (Baltimore); 2023 Jan; 102(4):e32815. PubMed ID: 36705371 [TBL] [Abstract][Full Text] [Related]
4. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography]. Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665 [TBL] [Abstract][Full Text] [Related]
5. OCTA changes following loading phase with intravitreal aflibercept for DME. Kansal V; Colleaux K; Rawlings N Can J Ophthalmol; 2023 Oct; 58(5):480-490. PubMed ID: 35526615 [TBL] [Abstract][Full Text] [Related]
6. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578 [TBL] [Abstract][Full Text] [Related]
7. EFFECT OF BASELINE CENTRAL RETINAL THICKNESS ON THE RESULTS OF TREATMENT OF DIABETIC MACULAR EDEMA WITH AFLIBERCEPT: REAL-LIFE EVIDENCE IN THE CZECH REPUBLIC. Němčanský J; Stepanov A; Veith M; Koubek M; Kopecký A; Němčanská S; Beran D; Studnička J Cesk Slov Oftalmol; 2022; 78(2):64-70. PubMed ID: 35477246 [TBL] [Abstract][Full Text] [Related]
8. The Impact of Laboratory Findings and Optical Coherence Tomography Biomarkers on Response to Intravitreal Anti-VEGF Treatment in Patients with Diabetic Macular Edema. Chatziralli I; Dimitriou E; Lambadiari V; Kazantzis D; Kapsis P; Theodossiadis G; Theodossiadis P; Sergentanis TN Semin Ophthalmol; 2022 Jul; 37(5):668-675. PubMed ID: 35468026 [TBL] [Abstract][Full Text] [Related]
9. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment. Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605 [TBL] [Abstract][Full Text] [Related]
10. Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections. Chang YC; Huang YT; Hsu AY; Meng PP; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Lin JM; Chen WL; Tsai YY Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984630 [No Abstract] [Full Text] [Related]
11. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Bahrami B; Hong T; Zhu M; Schlub TE; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195 [TBL] [Abstract][Full Text] [Related]
12. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema. Maggio E; Mete M; Sartore M; Bauci F; Guerriero M; Polito A; Pertile G Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):807-815. PubMed ID: 34661731 [TBL] [Abstract][Full Text] [Related]
13. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors. Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955 [TBL] [Abstract][Full Text] [Related]
14. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. Ozsaygili C; Duru N Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970 [TBL] [Abstract][Full Text] [Related]
15. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027 [TBL] [Abstract][Full Text] [Related]